[Sereda Andrey]

31. Eriksson Bl. Ekman S. Lindbratt S. Baur M. Bach D. Torholm C. Kalebo P. Close P. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79:326-33.
32. Eriksson Bl. Wille-J0rgenson P. Kalebo P. Mouret P. Rosencher N. Bosch P. Baur M. Ekman S. Bach D. Lindbratt S, Close P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997:337: 1329-35.
33. Fisher WD. Eriksson Bl. Bauer KA. Borris L. Dahl OE. Gent M. Haas S. Homering M. Huisman MV. Kakkar AK, Kдlebo P, Kwong LM, Misselwitz F. Turpie AG. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost. 2007:97:931-7.
34. Fong YK. Ruban P. Yeo SJ. Lee BP. Lo NN. Seow KH. Ng SC. Use of low molecular weight
heparin for prevention of deep vein thrombosis in total knee arthroplasty—a study of its efficacy in an Asian population. Ann Acad Med Singapore. 2000;29:439-41.
35. Francis CVV. Pellegrini VD Jr. Marder VJ, Totterman S. Harris CM. Gabriel KR. Azodo MV. Liebert KM. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911-5.
36. Francis CVV. Pellegrini VD Jr. Totterman S. Boyd AD Jr. Marder VJ. Leibert KM. Stulberg BN. Ayers DC. Rosenberg A, Kessler C, Johanson NA. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997:79:1365-72.
37. Francis CW. Berkowitz SD. Comp PC. Lieberman JR. Ginsberg JS. Paiement G. Peters GR. Roth AW. McElhattan J. Colweil CW Jr; EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003:349: 1703-12.
38. Francis CW. Davidson BL. Berkowitz SD. Lotke PA. Ginsberg JS. Lieberman JR. Webster AK. Whipple JP. Peters GR. Colweil CW Jr. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 2002:137:648-55.
39. Freedman KB. Brookenthal KR. Fitzgerald RH Jr. Williams S. Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82:929-38.
40. Geerts WH. Pineo GF. Heit JA. Bergqvist D. Lassen MR. Colwell CW. Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004:126(3 Suppl):338S-400S.
41. Gonzalez Delia Valle A. Serota A. Go G. Sorriaux G. Sculco TP. Sharrock NE. Salvati EA. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res. 2006;444:146-53.
42. Guyatt G. Schunemann HJ. Cook D. Jaeschke R. Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004:126(3 Suppl): 179S-187S.
43. Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2008 Dec;90(12):2764-80.
44. Haas SB, Barrack RL, Westrich G. Venous thromboembolic disease after total hip and knee arthroplasty. Instr Course Lect. 2009;58:781-93.
45. Haralson RH III. Getting your share of the CMS P4P 2007 bonus payments. 2007 Jan/Feb. [Ссылки доступны только зарегистрированным пользователям ]. Accessed 2008 Jan 25.
46. Heit JA. Elliott CG. Trowbridge AA. Morrey BF. Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboem-bolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000:132:853-61.
47. Hirsch J. Therapeutic range for the control of oral anticoagulant therapy. Arch Intern Med, 1985;145:1187-8.
48. Hirsh J, Levine MN. The optimal intensity of oral anticoagulant therapy. JAMA. 1987;258;2723-6.
49. Hirsh J. O'Donnell M. Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007:116:552-60.
50. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865-75.
51. Howie C. Hughes H. Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period; a population-based study. J Bone Joint Surg Br. 2005;87;1675-80.
52. Hull R. Raskob G. Pineo G. Rosenbloom D. Evans W. Mallory T. Anquist K. Smith F. Hughes G. Green D. Elliot CG, Panju A, Brant R. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med, 1993;329:1370-6.
53. Hull RD. Pineo GF. Francis C. Bergqvist D. Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000:160:2208-15.
54. Imberti D, Ageno W, Carpenedo M. Retrievable vena cava filters: a review. Curr Opin Hematol. 2006:13:351-6.
55. Kakkar W. Howes J. Sharma V. Kadziola Z. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb Haemost. 2000:83:523-9.
56. Katz JN. Losina E. Barrett J. Phillips CB. Mahomed NN. Lew RA. Guadagnoli E. Harris WH. Poss R, Baron JA. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am. 2001;83;1622-9.
57. Keeney JA. Clohisy JC. Curry MC. Maloney WJ. Efficacy of combined modality prophylaxis including short-duration warfarin to prevent venous thromboembolism after total hip arthroplasty. J Arthroplasty. 2006:21:469-75.
58. Kurtz S. Ong K. Lau E. Mowat F. Halpem M. Projections of primary and revision hip and knee
arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89;780-5.
59. Lachiewicz PF, Soileau ES. Multimodal prophylaxis for THA with mechanical compression. Clin Orthop Relat Res. 2006;453:225-30.
60. Lachiewicz PF. Kelley SS. Haden LR. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. A prospective, randomised study. J Bone Joint Surg Br. 2004;86:1137-41.